Articles On IDT Australia (ASX:IDT)
Title | Source | Codes | Date |
---|---|---|---|
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
The world is experiencing a ‘shroom boom’ Psychedelics are expected to follow in cannabis’ explosive footstep And here’s how the ASX weed stocks have performed, sorted by winners over the past week For years, people have frowned upon ps... |
Stockhead | IDT | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | IDT | 1 year ago |
Closing Bell: US debt ceiling progress sees ASX fare okay; Paladin comes out swinging
The ASX 200 rose 0.30%, as the day turned out flattish to half decent, rather than deadset flattened The fact US Congress types look like reaching a debt-ceiling deal no doubt helped matters Healthcare and tech stonks are up, while Paladin... |
Stockhead | IDT | 1 year ago |
Weed Week: Cannabis helps chronic pain and insomnia, and here’s what the TGA rules say
Research in Australia shows marijuana helps with chronic pain and insomnia The rules around getting prescriptions for medicinal cannabis A quick look at the winners and losers of ASX weed stocks Sufferers of chronic pain and insomnia ha... |
Stockhead | IDT | 1 year ago |
Weed Week: New studies confirm cannabis alleviates cancer pain, cuts need for opioids, and improves sleep
Studies confirm that cannabis relieves pain in cancer patients In addition, cannabis also improves sleep and cognitive function in cancer patients We take a look at the biggest movers in ASX weed stocks over the past week It’s now offic... |
Stockhead | IDT | 1 year ago |
ASX April Winners: Mid and small caps outperform blue-chip peers as gold stocks keep up rally
The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru... |
Stockhead | IDT | 1 year ago |
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales
Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s... |
Stockhead | IDT | 1 year ago |
Weed Week: 420 reminds us that cannabis stocks may be down, but by no means out
The 420 Day is unofficially the World Marijuana Day, and we look at the possible origins of this day Cannabis stocks have been falling, but there’s still a lot of promise We take a look at the cannabis stocks on the ASX over the past week... |
Stockhead | IDT | 1 year ago |
Weed Week: Most Aussies still use illicit cannabis, but more are now turning to prescriptions
The number of Aussies using legal instead of illicit medical cannabis is rising The main reason for using prescribed medicinal cannabis was chronic pain, says Sydney Uni survey We take a look at what made the news in ASX weed stocks this p... |
Stockhead | IDT | 1 year ago |
ASX Biotech Stocks: Noxopharm eyes new mRNA product with market forecast to hit US$128 billion by 2030
Noxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence extension to manufacture advanced injectable therapies PharmAust patient in motor neurone disease trial elevated to Cohort 2 Biotech company N... |
Stockhead | IDT | 1 year ago |
IDT achieves milestone with TGA-approved expansion of manufacturing
IDT Australia (ASX:IDT) has announced that the TGA has expanded the licensing conditions covering its Aseptic Sterile Processing facility. |
BiotechDispatch | IDT | 1 year ago |
WEED WEEK: Wellnex teams up with Chemist Warehouse for new cannabis products
Chemist Warehouse joins WNX JV to develop new cannabis products Neurotech launches new clinical program for its NTI164 drug in Rett Syndrome InhaleRx nabs approval for Phase 1 IRX211 clinical trial for Complex Regional Pain Syndrome Wel... |
Stockhead | IDT | 1 year ago |
CLOSING BELL: Aussies find a cost of living crisis fix, by stealing everything not nailed down
The ASX slid to close flat today, after realising we were in danger of making some money Materials and Energy enjoyed a boost from Chinese manufacturing data Retail theft rates have soared as the cost of living crisis hits hard around the... |
Stockhead | IDT | 1 year ago |
Weed Week: Musk gives the go-ahead for cannabis advertising on Twitter in the US
Twitter to allow cannabis companies to advertise in US states where it’s legal Elixnol comes out on top with CannaCare Health arbitration awarded in their favour Avecho expands CBD soft-gel capsule trials with the Lambert Initiative Twi... |
Stockhead | IDT | 1 year ago |
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care
The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry The US FDA announced last week that:... |
Stockhead | IDT | 1 year ago |
Weed Week: Codeine demand drops when recreational cannabis is legal, study finds
US States who allow recreational cannabis see less codeine demand WA GP wants Snoop Dogg to drop into parliament to chat cannabis reform Neurotech nabs pre-submission meeting with US FDA for CBD drug NTI164 A Cornell University study ha... |
Stockhead | IDT | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | IDT | 1 year ago |
Weed Week: Decriminalising cannabis could save Aussie tax payers billions every year
Penington Institute says pot-related law enforcement costs us $1.7 billion a year Local cannabis is missing out on international and domestic market opportunities Aussie medicinal cannabis revenue was around $230 million in 2021 Decri... |
Stockhead | IDT | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | IDT | 1 year ago |
Weed Week: More US states vote to legalise cannabis and Czech Republic to follow in Germany’s footsteps
Two more US states join the 19 that already allow legal recreational cannabis use ECS Botanics’ Victorian medical cannabis facility is safe from flooding in the state, so far Cann looks to commercialise its Satipharm CBD capsules for over-... |
Stockhead | IDT | 2 years ago |
Weed Week: Germany’s plans to legalise cannabis rekindle North American investment spark in Europe
Germany looks to legalise recreational cannabis and US and Canadian companies are paying attention Neurotech reports success with its cannabis-based drug for paediatric autism symptoms ECS Botanics has sold its Tasmanian business and a... |
Stockhead | IDT | 2 years ago |
Dr Boreham’s Crucible: Go Woke, go broke? Early signs say no concerns with this pyschedelic IPO
Amid a worldwide surge of interest in using psychedelic substances to treat stubborn mental health conditions, the ASX possibly soon could host its first pure-play drug developer in this (mind) expanding field. The private Woke Pharmaceutic... |
Stockhead | IDT | 2 years ago |
Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?
We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month There were 191 ASX IPOs in... |
Stockhead | IDT | 2 years ago |
IDT Australia announces new appointments to board of directors
Australian pharmaceutical manufacturing company IDT Australia (ASX:IDT) has announced the appointment of Mark Simari and Geoffrey Sam OAM to its board. |
BiotechDispatch | IDT | 2 years ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | IDT | 2 years ago |
Weed Week: The lazy stoner stereotype is a myth and this Aussie uni wants to study home grown cannabis
Cambridge says cannabis smokers are not actually lazy, that’s a myth USyd wants to test home-grown cannabis in the ACT Incannex joins the big leagues S&P/ASX300 index It turns out that the lazy stoner stereotype is actually a myth,... |
Stockhead | IDT | 2 years ago |
ASX Health Stocks: Patrys wins fresh grant, IDT does not and Next Science is off to sell stuff in Canada
Patrys gets research grant to progress lead drug Next Science gets Canada license Bad news for IDT Australia Cancer fighter Patrys (ASX: PAB) has received a new $100k research grant to progress lead drug deoxymabs in treating Metastatic... |
Stockhead | IDT | 2 years ago |
Top 10 at 10: Which ASX stocks are soaring and slipping today?
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IDT | 2 years ago |
Weed Week: Legal use of medicinal cannabis in Australia on the rise, Lambert Initiative says
Researchers say data shows transition from illicit to legal use of cannabis Medicinal users are at 37%, compared to 2.5% in 2018 Regulations, quality control and costs still barriers for legal week users New research from the University... |
Stockhead | IDT | 2 years ago |
Weed Week: Ice-T plans to open dispensary and Snoop Dogg’s venture capital firm backs weed snacks
Ice-T is opening a cannabis dispensary in New Jersey this year Snoop Dogg’s venture capital firm led a seed funding round for TSUMo Snacks Incannex ramps up development and manufacturing of IHL-216A drug New Jersey has given Ice-T the gre... |
Stockhead | IDT | 2 years ago |
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
Mysterious pink glow over Mildura Thailand businesses go nuts for CBD desserts and bubble tea ECS nabs $2m commercial loan facility to invest in new capacity ICYMI a mysterious pink glow above Mildura sent residents into a bit of a frenzy... |
Stockhead | IDT | 2 years ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | IDT | 2 years ago |
Weed Week: An Aussie medicinal cannabis farm for sale and crypto ATMs in weed dispensaries
ECS is selling its medicinal cannabis farm in Tasmania Crypto ATMs are now a thing in weed dispensaries in the US Zelira Therapeutics nabs regulatory approval in Germany for insomnia medication Ever fancied your own cannabis farm? Well, t... |
Stockhead | IDT | 2 years ago |
How did ASX biotech shares perform in FY22?
ASX biotech shares were hammered in FY22 with the sector facing heavy losses, in line with the wider technology sector. The ETFs S&P Biotech ETF (ASX: CURE), an index fund tracking the global biotech sector, is down almost 24% this y... |
Motley Fool | IDT | 2 years ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | IDT | 2 years ago |
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
Retail and independent cannabis lounges could be opening soon in Vegas Cann Group gets good manufacturing practice (GMP) licence for its Mildura facility Bod plans to launch a low dose CBD schedule 3 product into the Australian market ... |
Stockhead | IDT | 2 years ago |
Top 10 at 10: The ASX stocks darting and dawdling in early trade Friday
Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | IDT | 2 years ago |
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
A Thai university says adding cannabis to chicken feed has positive results on meat and egg quality Aussie cannabis campaigner now a Member of the Order of Australia MGC Pharma’s CBD treatment proves effective against brain tumors Chian... |
Stockhead | IDT | 2 years ago |
Closing Bell: Small caps show big heart with unlikely rise
Emerging Companies (XEC) index jumps more than 2% before trimming gains Benchmark ASX200 down 0.15% Greentech Metals up over 120%, in trading halt Inspired by strength in gold and metals Aussie small caps have bounced off the canvas... |
Stockhead | IDT | 2 years ago |
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Boston Beer Co launches cannabis iced tea in Canada University of Sydney says using CBD and driving is no worries Emyria reports positive Phase 1 study results for ultra-pure CBD capsule The Boston Beer Co is launching a line of cannabis-... |
Stockhead | IDT | 2 years ago |
Weed Week: Woody Harrelson opens weed dispensary and Byron Bay could be home to a cannabis resort
Actor Woody Harrelson has opened a cannabis store in West Hollywood Releaf has plans for a weed wellness retreat in Byron Bay Incannex wants to buy out APIRx It’s not surprising that Woody Harrelson loves weed – the actor was actually... |
Stockhead | IDT | 2 years ago |
Weed Week: Jim Belushi headlines cannabis expo and the first legal seedbank established in Denmark
Actor and cannabis farmer Jim Belushi is headlining the Grow Up Conference and Expo next month Franchise Global Health has established the first legal seedbank in Denmark Botanix nabs FDA Qualified Infection Disease Product designation for... |
Stockhead | IDT | 2 years ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | IDT | 2 years ago |
Weed Week: US seed bank launches 4/20 day NFT collection and Washington has a cannabis tax holiday
US Seed Connect launched Cannabis Crypto Seed Headz NFT Washington launches week-long cannabis tax holiday Medlab clinical makes moves in the Northern Hemisphere with manufacturing deal Wednesday was 4/20 day – while it’s more of an unoff... |
Stockhead | IDT | 2 years ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | IDT | 2 years ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | IDT | 2 years ago |
Who got what in the healthcare budget, and which ASX stocks could benefit
The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade... |
Stockhead | IDT | 2 years ago |
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
The ACIC says weed consumption increased in cities and regions ROO receives USA design patent approval for its Heat Exchange Probe EMD has launched its second ultra-pure CBD capsule, the EMD-RX7 The latest Australian Criminal Intelligen... |
Stockhead | IDT | 2 years ago |
Closing Bell: Oil & gas juniors soar as ASX microcaps notch up a hat-trick
Make it three on the trot for the ASX microcap Emerging Companies index, which rose by more than 1% for the third straight session on Friday. The gains follow a broader turnaround in global risk sentiment this week, following the initial sh... |
Stockhead | IDT | 2 years ago |
IDT Australia (ASX:IDT) unsuccessful in first round of manufacturing initiative
IDT Australia (IDT) has been unsuccessful in its application for a grant under the Federal Government’s Modern Manufacturing Initiative (MMI) While awaiting an outcome of the MMI Manufacturing Collaboration grant, IDT says it delivered Aus... |
themarketherald.com.au | IDT | 2 years ago |